Table 5.

Codelivery of photosensitizer and hyperthermia agent drugs based on nanocarriers.

Nanoparticle	Photosensitizers	Hyperthermia Agents	Tumor	Data Sources	Findings	Ref
Cancer cell membrane-cloaked Ce6-loaded Janus magnetic mesoporous organosilica NPs (CM@M-MON@Ce6)	Chlorin e6 (Ce6)	Magnetic mesoporous silica nanoparticles (M-MSNs)	4T1	In vitro, Animals	It exhibited the function of REDOX/PH double stimulation to induce PS release and matrix degradation. Increased the ability of targeted tumor aggregation and prolonged blood circulation time. Enhanced anticancer activity, simultaneously triggering a series of immunogenic cell death, resulting in a synergistic tumor-specific immune response.	[174] 2019
Ultramagnetic photosensitive liposomes	Foscan	Iron oxide NPs	SKOV-3	In vitro, Animals	The combination of photodynamic and magnetothermal therapy triggered the synergistic action of apoptotic signaling pathways, leading to complete eradication of tumor cells.	[175] 2015
Magneto low-density nanoemulsion (MLDE)	Chlorin e6 (Ce6)	Iron oxide NPs	MCF-7	In vitro	Improved the stability and biocompatibility of drugs. Identified the low-density lipoprotein receptor on the surface of tumor cells and improved the targeting selectivity of drugs.	[176] 2018